Role of Biomarkers in Translational Science

In the post-genomic time, it has turned out to be obvious that hereditary changes alone are not adequate to see most sickness forms including tumor. Genome sequencing has uncovered an unpredictable arrangement of hereditary changes in disease, for example, point transformations, chromosomal misfortunes, quality intensifications and telomere shortening that drive harmful development through specific signalling pathways.
Proteome-based methodologies are vital supplements to genomic information and give essential data of the objective driver particles and their post-translational changes. By applying quantitative mass spectrometry, this is an elective method to distinguish biomarkers for early diagnosis and personalized medicine.
  • Improving cancer patient care through translational science
  • Safety, efficacy and PK/PD biomarkers in drug development
  • Biomarkers for early identification of neurological disease
  • Biomarker development in metabolic and cardiovascular diseases
  • Predictive biomarkers for drug development
  • Translating biomarkers from discovery stages through to exploratory clinical testing
  • New advances in biomarker technologies and platform